Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

32.66 +4.11 (+14.41%)
Streaming Delayed Price Updated: 9:47 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)
Via AB Newswire
News headline image
Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip? ↗
A disappointing result for its oral obesity candidate hammered the stock price. 
Via The Motley Fool
News headline image
Here's Why Viking Therapeutics Bounced Back Today ↗
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing. 
Via The Motley Fool
News headline image
Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny
The financial markets are a dynamic arena where fortunes can shift rapidly, and the past week has seen two prominent companies, Palantir Technologies Inc. (NYSE: PLTR) and Viking Therapeutics (NASDAQ:... 
Via MarketMinute
Topics Artificial Intelligence
Wall Street Defends Viking As Weight Loss Pill Trial Results Trigger Stock Rout; Retail Calls Selloff ‘Unjustified’ ↗
Via Stocktwits
Intel, Palantir, Home Depot, Viking, Nio: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
News headline image
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug? ↗
Viking (VKTX) stock plunged 42% after its obesity pill trial. Experts are split: some call it a $129 Strong Buy, others say it's inferior. 
Via Benzinga
News headline image
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns
San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet... 
Via MarketMinute
News headline image
Palantir, AMD, Oracle, Viking And Nvidia: Why These 5 Stocks Are On Investors' Radars Today ↗
U.S. stock indices closed mixed on Tuesday, with the Dow Jones Industrial Average edging up 0.02% to 44,922.27. 
Via Benzinga
Topics Stocks
This Drugmaker Stock Slumped 36% In Tuesday’s Premarket Session: Here’s Why ↗
Via Stocktwits
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme' ↗
Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off is excessive. 
Via Benzinga
News headline image
Tech Stocks Drop, Palantir Plunges Over 8%: What's Moving Markets Tuesday? ↗
Tech stocks pulled back on Tuesday as the absence of fresh bullish catalysts prompted investors to take profits after the recent months-long rally. 
Via Benzinga
News headline image
Nasdaq Down Over 300 Points; Medtronic Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Why Novo Nordisk Stock Popped Today ↗
For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Crashed Today ↗
Viking's new GLP-1 weight loss pill is pretty great -- but is it enough to turn the company profitable? 
Via The Motley Fool
News headline image
US Stocks Mixed; Home Depot Shares Gain After Q2 Results ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks ↗
Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity patients versus placebo. 
Via Benzinga
News headline image
Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill ↗
Shares lost more than a third of their value after Viking unveiled mixed results for its oral VK2735. 
Via Investor's Business Daily
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stock Market Today: S&P 500 Slips, Dow Futures Rise—Intel, Palo Alto, Home Depot In Focus ↗
U.S. stock futures were fluctuating on Tuesday following mostly unchanged moves from Monday. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Stocks
News headline image
Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond ↗
Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for something BIG." 
Via Benzinga
Topics Bonds
News headline image
Predicting the Next Rule Breaker Buyout ↗
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Viking Therapeutics Stock Zoomed 5% Higher Today ↗
The company is a front-runner in the race to develop an orally administered weight loss drug. 
Via The Motley Fool
News headline image
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
Via AB Newswire
News headline image
1 Beaten-Down Stock That Could Soar by the End of the Year ↗
The drugmaker has a major catalyst on the way. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.